
Sanofi announces positive topline results demonstrated by olipudase alfa, first and only investigational therapy in late-stage development for ASMD

Olipudase alfa, an investigational recombinant human acid sphingomyelinase, demonstrated positive results in two separate clinical trials evaluating olipudase alfa for the treatment of acid sphingomyelinase deficiency (ASMD) in adult and pediatric patients. Olipudase alfa is the first and only investigational enzyme replacement therapy in late-stage development for the treatment of ASMD. [Click here](#) to read more.

www.sanofigenzyme.com